PLEASANTON, Calif., Sept. 13 /PRNewswire/ -- QuantaLife, a new life science tool company developing the third generation of PCR, has received an NIH grant totaling ~$6 million over 5 years for the development of rapid, cost-effective technology for detecting methicillin-resistant Staphylococcus aureus (MRSA) infections. The grant, from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), part of the National Institutes of Health, will fund the project.
QuantaLife is currently building a new instrument system for droplet digital™PCR, the first of its kind, that will detect and quantify DNA/RNA targets. The NIH grant will allow the company to broaden its product pipeline to build a platform for detecting the antibiotic resistant bacteria that cause MRSA infections. Clinical testing will be done in collaboration with the University of Mississippi Medical Center.
Dr. Ben Hindson, Chief Science Officer, said, "The award provides independent validation of QuantaLife's novel ddPCR™ platform and will accelerate the development of our next-generation diagnostic platform."
The Third Generation of PCRQuantaLife is an innovative company developing a complete system to quantify DNA molecules by droplet digital PCR. Marking a new era in the reliability and affordability of PCR testing, the ddPCR system delivers an absolute measure of target molecules with unrivaled quantitative resolution. © 2010 QuantaLife, Inc. All rights reserved. QuantaLife, droplet digital PCR and ddPCR are trademarks of QuantaLife, Inc. QuantaLife, Inc.All other trademarks are the property of their respective owners.
|SOURCE QuantaLife, Inc.|
Copyright©2010 PR Newswire.
All rights reserved